How EOM Pharmaceutical Holdings is positioning EOM613 as a potential multi-cytokine therapy for cancer cachexia
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
Why the first patient dosed in CatalYm’s VINCIT trial matters more than it seems.
CatalYm has dosed the first patient in its visugromab Phase 2/3 cachexia trial. Read why this oncology move could matter far beyond weight gain.